CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...